Shore Capital Reaffirms “Buy” Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by equities research analysts at Shore Capital in a report issued on Friday, Marketbeat Ratings reports.

A number of other equities research analysts also recently issued reports on AZN. Berenberg Bank restated a “buy” rating and set a GBX 140 ($1.81) price target on shares of AstraZeneca in a research note on Monday, January 27th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 7,542.80 ($97.46).

AstraZeneca Trading Up 0.4 %

AstraZeneca stock opened at £120.72 ($155.99) on Friday. The business has a 50-day simple moving average of £113.08 and a two-hundred day simple moving average of £114.21. The company has a market cap of £232.27 billion, a P/E ratio of 33.09, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a 52-week low of GBX 9,670 ($124.95) and a 52-week high of £133.88 ($172.99). The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.